Comparison of Receptor Profiles Between Primary Tumors and Isolated Thoracic Metastasesin Breast Cancer
DOI:
https://doi.org/10.82582/thorac.95Keywords:
Breast Neoplasms, Erb-b2 Receptor Tyrosine Kinases, Neoplasm Metastasis, Receptors, Estrogen, Receptors, ProgesteroneAbstract
Introduction: Receptor status may change during metastatic progression, potentially altering therapeutic decisions and outcomes. This study aimed to determine ER, PR, and HER2 changes in thoracic metastases (pleura, lung, lymph node, pericardium, chest wall) of breast cancer and to evaluate their impact on survival.
Methods: Data of 46 women who underwent an interventional procedure for thoracic metastasis of breast cancer and had available ER/PR/HER2 assessment in both primary and corresponding metastatic tissues were retrospectively analyzed. Post-metastasis survival was calculated from the date of histopathological confirmation of metastatic disease. The associations of primary breast cancer receptor status, metastatic receptor status, and receptor conversion at metastasis with survival outcomes were investigated.
Results: The pleura was the most common metastatic site (54.3%). In primary tumors, ER, PR, and HER2 positivity rates were 87%, 63%, and 21%, respectively, whereas in metastatic tissues they were 69.6%, 45.7%, and 25.6%. ER loss was observed in 17.4% of cases, with no gain detected. PR loss occurred in 23.9% and gain in 6.5%, while HER2 loss and gain were observed in 7.0% and 11.6% of cases, respectively. Univariate analysis identified pleural metastasis (HR=3.442, p=0.017), ER negativity in metastatic tissue (HR=3.306, p=0.008), PR negativity in metastatic tissue (HR=2.793, p=0.037), and ER loss (HR=3.095, p=0.022) as adverse prognostic factors. In multivariate analysis, pleural metastasis (HR=4.424, p=0.009) and ER loss (HR=3.669, p=0.010) remained independent predictors of poor survival. No significant association was found between HER2 status and survival.
Conclusion: ER loss and pleural metastasis are independent adverse prognostic factors in thoracic metastases of breast cancer. These findings related to tumor biology, particularly receptor status changes between primary and metastatic tumors, may help guide personalized therapeutic approaches.
Downloads
References
Yi ZB, Yu P, Zhang S, Wang WN, Han YQ, Ouyang QC, et al. Profile and outcome of receptor conversion in breast cancer metastases: a nation-wide multicenter epidemiological study. Int J Cancer. 2021;14:692-701. doi:10.1002/ijc.33227
Van Poznak C, Somerfield MR, Bast RC, Cristofanilli M, Goetz MP, Gonzalez-Angulo AM, et al. Use of biomarkers to guide decisions on systemic therapy for women with metastatic breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol. 2015;33:2695-704. doi:10.1200/JCO.2015.61.1459
Lu Y, Tong Y, Chen X, Shen K. Association of biomarker discrepancy and treatment decision, disease outcome in recurrent/metastatic breast cancer patients. Front Oncol. 2021;11:638619. doi:10.3389/fonc.2021.638619
McAnena PF, McGuire A, Ramli A, Curran C, Malone C, McLaughlin R, et al. Breast cancer subtype discordance: impact on post-recurrence survival and potential treatment options. BMC Cancer. 2018;18:203. doi:10.1186/s12885-018-4101-7
National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Breast Cancer. Version 1.2026 [accessed Jan 2026]. Available at: https://www.nccn.org/professionals/physician_gls/pdf/breast.pdf
Cardoso F, Senkus E, Costa A, Papadopoulos E, Aapro M, André F, et al. 4th ESO-ESMO International Consensus Guidelines for Advanced Breast Cancer (ABC 4). Ann Oncol. 2018;29:1634-57. doi:10.1093/annonc/mdy192
Cazzaniga ME, Pronzato P, Amoroso D, Arpino G, Atzori F, Beano A, et al. Survival outcomes of luminal metastatic breast cancer patients according to changes in molecular subtype at re-biopsy: insights from the GIM-13-AMBRA study. Cancers. 2025;17:1715. doi:10.3390/cancers17101715
Lindstrom LS, Karlsson E, Wilking UM, Johansson U, Hartman J, Lidbrink EK, et al. Clinically used breast cancer markers such as estrogen receptor, progesterone receptor, and human epidermal growth factor receptor 2 are unstable throughout tumor progression. J Clin Oncol. 2012;30:2601-8. doi:10.1200/JCO.2011.37.2482
Shiino S, Ball G, Syed BM, Kurozumi S, Green AR, Tsuda H, et al. Prognostic significance of receptor expression discordance between primary and recurrent breast cancers: a meta-analysis. Breast Cancer Res Treat. 2022;191:1-14. doi:10.1007/s10549-021-06390-6
Duffy MJ, Harbeck N, Nap M, Molina R, Nicolini A, Senkus E, et al. Clinical use of biomarkers in breast cancer: Updated guidelines from the European Group on Tumor Markers (EGTM). Eur J Cancer. 2017;75:284-98. doi:10.1016/j.ejca.2017.01.017
Amir E, Miller N, Geddie W, Freedman O, Kassam F, Simmons C, et al. Prospective study evaluating the impact of tissue confirmation of metastatic disease in patients with breast cancer. J Clin Oncol. 2012;30:587-92. doi:10.1200/JCO.2010.33.5232
Zhao W, Sun L, Dong G, Wang X, Jia Y, Tong Z. Receptor conversion impacts outcomes of different molecular subtypes of primary breast cancer. Ther Adv Med Oncol. 2021;13:17588359211012982. doi:10.1177/17588359211012982
Shen J, Xu L, Shi J, Zhao L, Shi S, Feng J, et al. Prognostic Value and Influence of Receptor Conversion on Treatment Regimen in Metastatic Breast Cancer at the First Time of Recurrence. Oncol Res Treat. 2020;43:620-7. doi:10.1159/000509673
Francis IM, Alath P, George SS, Jaragh M, Al Jassar A, Kapila K. Metastatic breast carcinoma in pleural fluid: Correlation of receptor and HER2 status with the primary carcinoma-a pilot study. Diagn Cytopathol. 2016;44:980-6. doi:10.1002/dc.23607
Niikura N, Liu J, Hayashi N, Mittendorf EA, Gong Y, et al. (reference incomplete in document)
Schrijver W, Suijkerbuijk KP, van Gils CH, van der Wall E, Moelans CB, van Diest PJ. Receptor conversion in distant breast cancer metastases: a systematic review and meta-analysis. J Natl Cancer Inst. 2018;110:568-80. doi:10.1093/jnci/djx273
Grinda T, Joyon N, Lusque A, Lefevre S, Arnould L, Penault-Llorca F, et al. Phenotypic discordance between primary and metastatic breast cancer in the large-scale real-life multicenter French ESME cohort. NPJ Breast Cancer. 2021;7:41. doi:10.1038/s41523-021-00252-6
Sunden M, Norgren S, Lundqvist R, Andersson A, Sund M, Hemmingsson O. Receptor conversion and survival in breast cancer liver metastases. Breast Cancer Res. 2023;25:105. doi:10.1186/s13058-023-01706-4
Yoshino R, Takahashi K, Hatanaka N, Ito A, Ujiiie N, Yasuda S, et al. Analysis of prognostic factors after pulmonary resection for metastatic breast cancer: a 23-year single-institution retrospective study. Gen Thorac Cardiovasc Surg. 2026;74:309-16. doi:10.1007/s11748-025-02207-1
Connolly JE Jr, Erasmus JJ, Patz EF Jr. Thoracic manifestations of breast carcinoma: metastatic disease and complications of treatment. Clin Radiol. 1999;54:487-94. doi:10.1016/s0009-9260(99)90844-9
Butow PN, Coates AS, Dunn SM. Psychosocial predictors of survival: metastatic breast cancer. Ann Oncol. 2000;11:469-74. doi:10.1016/s0009-9260(99)90844-9
Li S, Li C, Shao W, Liu X, Sun L, Yu Z. Survival analysis and prognosis of patients with breast cancer with pleural metastasis. Front Oncol. 2023;13:1104246. doi.org/10.3389/fonc.2023.1104246
Light RW. Malignant pleural and pericardial effusions. In: Sellke FW, Rutherford RB, Brunicardi FC, editors. Sabiston & Spencer Surgery of the Chest. 10th ed. Philadelphia: Elsevier; 2024. p. 554-66.
Deluche E, Antoine A, Bachelot T, Lardy-Cleaud A, Dieras V, Brain E, et al. Contemporary outcomes of metastatic breast cancer among 22,000 women from the multicentre ESME cohort 2008-2016. Eur J Cancer. 2020;129:60-70. doi:10.1016/j.ejca.2020.01.016
Aurilio G, Disalvatore D, Pruneri G, Bagnardi V, Viale G, Curigliano G, et al. A meta-analysis of oestrogen receptor, progesterone receptor and human epidermal growth factor receptor 2 discordance between primary breast cancer and metastases. Eur J Cancer. 2014;50:277-89. doi:10.1016/j.ejca.2013.10.004
Dowling GP, Keelan S, Cosgrove NS, Daly GR, Giblin K, Toomey S, et al. Receptor discordance in metastatic breast cancer: a review of clinical and genetic subtype alterations from primary to metastatic disease. Breast Cancer Res Treat. 2024;207:471-6. doi:10.1007/s10549-024-07431-6
Downloads
Published
Data Availability Statement
Due to patient privacy and institutional restrictions, the datasets generated and/or analyzed during the current study are not publicly available but are available from the corresponding author upon reasonable request.
Issue
Section
License
Copyright (c) 2026 Author(s) (or their employer(s)) and THORAC 2024
This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.
